{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T13:04:13Z","timestamp":1795007053733,"version":"4.9.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"24","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,21]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Painful vertebral osteoporotic compression fractures (OCFs) are often treated with cement augmentation, although controversies exist as to whether or not this increases the secondary fracture risk. Prevention of secondary fracture includes treatment of underlying osteoporosis. The purposes of this study were to determine (1) whether cement augmentation increases the rate of secondary fracture compared with nonoperative management, (2) whether anti-osteoporotic medications reduce the rate of secondary fracture, and (3) the rate of osteoporosis treatment with medications following vertebral OCF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The PearlDiver database was queried for all patients with a diagnosis of OCF from 2015 to 2019. Patients were excluded if they were &lt;50 years old, had a diagnosis of spinal neoplasm or infection, or underwent lumbar fusion in the perioperative period. Secondary fracture risk was assessed using univariate and multivariate logistic regression analysis, with kyphoplasty, vertebroplasty, anti-osteoporotic medications, age, gender, and Elixhauser Comorbidity Index as variables.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>A total of 36,145 patients were diagnosed with an OCF during the study period. Of those, 25,904 (71.7%) underwent nonoperative management and 10,241 (28.3%) underwent cement augmentation, including 1,556 who underwent vertebroplasty and 8,833 who underwent kyphoplasty. Patients who underwent nonoperative management had a secondary fracture rate of 21.8% following the initial OCF, compared with 14.5% in the vertebroplasty cohort and 18.5% in the kyphoplasty cohort, which was not a significant difference on multivariate analysis. In the entire cohort, 2,833 (7.8%) received anti-osteoporotic medications and 33,312 (92.2%) did not. The rate of secondary fracture was 10.1% in patients who received medications and 21.9% in those who did not, which was a significant difference on multivariate analysis (odds ratio = 1.23, p &lt; 0.001).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Cement augmentation did not alter the rate of secondary fracture, whereas anti-osteoporotic medications significantly decreased the risk of subsequent OCF by 19%. Only 7.8% of patients received a prescription for an anti-osteoporotic medication following the initial OCF.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of Evidence:<\/jats:title>\n                    <jats:p>\n                      Therapeutic\n                      <jats:underline>Level III<\/jats:underline>\n                      . See Instructions for Authors for a complete description of levels of evidence.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.2106\/jbjs.22.00469","type":"journal-article","created":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T14:05:20Z","timestamp":1665583520000},"page":"2178-2185","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":26,"title":["Secondary Fracture Rate After Vertebral Osteoporotic Compression Fracture Is Decreased by Anti-Osteoporotic Medication but Not Increased by Cement Augmentation"],"prefix":"10.2106","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1777-2969","authenticated-orcid":false,"given":"Emily S.","family":"Mills","sequence":"first","affiliation":[{"name":"Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7513-3519","authenticated-orcid":false,"given":"Raymond J.","family":"Hah","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-1627","authenticated-orcid":false,"given":"Zoe","family":"Fresquez","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9400-2247","authenticated-orcid":false,"given":"Kevin","family":"Mertz","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5680-0643","authenticated-orcid":false,"given":"Zorica","family":"Buser","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5919-707X","authenticated-orcid":false,"given":"Ram K.","family":"Alluri","sequence":"additional","affiliation":[{"name":"Department of Orthopaedic Surgery, Keck School of Medicine, University of Southern California, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5833-9179","authenticated-orcid":false,"given":"Paul A.","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Orthopedic Surgery & Rehabilitation, University of Wisconsin, Madison, Wisconsin"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,12]]},"reference":[{"issue":"3","key":"bib1-20250430","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"J Bone Miner Res."},{"key":"bib2-20250430","author":"Bazell","year":"2019","journal-title":"Medicare cost of osteoporotic fractures."},{"issue":"3","key":"bib3-20250430","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.spinee.2018.08.004","article-title":"Rates of osteoporosis screening and treatment following vertebral fracture","volume":"19","author":"Barton","year":"2019","journal-title":"Spine J."},{"issue":"Suppl 4","key":"bib4-20250430","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1227\/NEU.0000000000000947","article-title":"Management of the Elderly With Vertebral Compression Fractures","volume":"77","author":"Goldstein","year":"2015","journal-title":"Neurosurgery."},{"issue":"1","key":"bib5-20250430","first-page":"217","article-title":"New fractures after vertebroplasty: adjacent fractures occur significantly sooner","volume":"27","author":"Trout","year":"2006","journal-title":"AJNR Am J Neuroradiol."},{"issue":"6","key":"bib6-20250430","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1056\/NEJMoa0900429","article-title":"A randomized trial of vertebroplasty for painful osteoporotic vertebral fractures","volume":"361","author":"Buchbinder","year":"2009","journal-title":"N Engl J Med."},{"issue":"8","key":"bib7-20250430","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3174\/ajnr.A2148","article-title":"Percutaneous vertebroplasty is not a risk factor for new osteoporotic compression fractures: results from VERTOS II","volume":"31","author":"Klazen","year":"2010","journal-title":"AJNR Am J Neuroradiol."},{"key":"bib8-20250430","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s11657-015-0229-0","article-title":"New vertebral fractures after vertebroplasty: 2-year results from a randomised controlled trial","volume":"10","author":"Staples","year":"2015","journal-title":"Arch Osteoporos."},{"issue":"1","key":"bib9-20250430","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.36076\/ppj.2017.1.E13","article-title":"Does Percutaneous Vertebroplasty or Balloon Kyphoplasty for Osteoporotic Vertebral Compression Fractures Increase the Incidence of New Vertebral Fractures? A Meta-Analysis","volume":"20","author":"Zhang","year":"2017","journal-title":"Pain Physician."},{"issue":"40","key":"bib10-20250430","doi-asserted-by":"crossref","first-page":"e12666","DOI":"10.1097\/MD.0000000000012666","article-title":"New vertebral fractures after osteoporotic vertebral compression fracture between balloon kyphoplasty and nonsurgical treatment PRISMA","volume":"97","author":"Li","year":"2018","journal-title":"Medicine (Baltimore)."},{"issue":"9","key":"bib11-20250430","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1007\/s00586-021-06899-w","article-title":"Does prophylactic vertebral augmentation reduce the refracture rate in osteoporotic vertebral fracture patients: a meta-analysis","volume":"30","author":"Chen","year":"2021","journal-title":"Eur Spine J."},{"issue":"Suppl 1","key":"bib12-20250430","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/GL-2020-0524SUPPL","article-title":"AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS\/AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2020 UPDATE","volume":"26","author":"Camacho","year":"2020","journal-title":"Endocr Pract."},{"issue":"3","key":"bib13-20250430","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/NOR.0000000000000672","article-title":"Secondary Fracture Prevention: Consensus Clinical Recommendations From a Multistakeholder Coalition","volume":"39","author":"Conley","year":"2020","journal-title":"Orthop Nurs."},{"issue":"10","key":"bib14-20250430","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","article-title":"Clinician\u2019s Guide to Prevention and Treatment of Osteoporosis","volume":"25","author":"Cosman","year":"2014","journal-title":"Osteoporos Int."},{"issue":"9077","key":"bib15-20250430","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet."},{"issue":"5","key":"bib16-20250430","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann Intern Med."},{"issue":"4","key":"bib17-20250430","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s00774-013-0505-2","article-title":"Once-weekly teriparatide reduces the risk of vertebral fracture in patients with various fracture risks: subgroup analysis of the Teriparatide Once-Weekly Efficacy Research (TOWER) trial","volume":"32","author":"Nakano","year":"2014","journal-title":"J Bone Miner Metab."},{"issue":"12","key":"bib18-20250430","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1359\/jbmr.080710","article-title":"Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial","volume":"23","author":"Silverman","year":"2008","journal-title":"J Bone Miner Res."},{"issue":"6","key":"bib19-20250430","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.clinthera.2020.04.011","article-title":"Effects of Injected Antiosteoporotic Medication Versus Oral Bisphosphonates on Rates of Repeated Vertebroplasty or Kyphoplasty","volume":"42","author":"Kao","year":"2020","journal-title":"Clin Ther."},{"key":"bib20-20250430","doi-asserted-by":"crossref","first-page":"635","DOI":"10.2147\/CIA.S80668","article-title":"Repeated vertebral augmentation for new vertebral compression fractures of postvertebral augmentation patients: a nationwide cohort study","volume":"10","author":"Liang","year":"2015","journal-title":"Clin Interv Aging."},{"key":"bib21-20250430","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.wneu.2021.09.131","article-title":"Percutaneous Vertebroplasty Combined with Zoledronic Acid in Treatment and Prevention of Osteoporotic Vertebral Compression Fractures: A Systematic Review and Meta-Analysis of Comparative Studies","volume":"157","author":"Tang","year":"2022","journal-title":"World Neurosurg."},{"issue":"1","key":"bib22-20250430","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00005650-199801000-00004","article-title":"Comorbidity measures for use with administrative data","volume":"36","author":"Elixhauser","year":"1998","journal-title":"Med Care."},{"issue":"2","key":"bib23-20250430","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/jbmr.1762","article-title":"Meta-analysis of vertebral augmentation compared with conservative treatment for osteoporotic spinal fractures","volume":"28","author":"Anderson","year":"2013","journal-title":"J Bone Miner Res."},{"issue":"15","key":"bib24-20250430","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"N Engl J Med."},{"issue":"10117","key":"bib25-20250430","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S0140-6736(17)32137-2","article-title":"Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial","volume":"391","author":"Kendler","year":"2018","journal-title":"Lancet."},{"key":"bib26-20250430","doi-asserted-by":"crossref","first-page":"115081","DOI":"10.1016\/j.bone.2019.115081","article-title":"Clinical effectiveness of denosumab, raloxifene, romosozumab, and teriparatide for the prevention of osteoporotic fragility fractures: A systematic review and network meta-analysis","volume":"130","author":"Simpson","year":"2020","journal-title":"Bone."},{"issue":"2","key":"bib27-20250430","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s12020-018-1824-9","article-title":"Use of antiosteoporotic drugs and calcium\/vitamin D in patients with fragility fractures: impact on re-fracture and mortality risk","volume":"64","author":"Degli Esposti","year":"2019","journal-title":"Endocrine."},{"issue":"4","key":"bib28-20250430","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.spinee.2019.10.020","article-title":"Declining trend in osteoporosis management and screening following vertebral compression fractures - a national analysis of commercial insurance and Medicare advantage beneficiaries","volume":"20","author":"Malik","year":"2020","journal-title":"Spine J."},{"issue":"5","key":"bib29-20250430","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society* Clinical Practice Guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"J Clin Endocrinol Metab."},{"key":"bib30-20250430","doi-asserted-by":"crossref","first-page":"115071","DOI":"10.1016\/j.bone.2019.115071","article-title":"Mind the gap: Incidence of osteoporosis treatment after an osteoporotic fracture - results of the Austrian branch of the International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)","volume":"142","author":"Malle","year":"2021","journal-title":"Bone."},{"issue":"3","key":"bib31-20250430","doi-asserted-by":"crossref","first-page":"213","DOI":"10.2106\/JBJS.20.00738","article-title":"Pelvic Fragility Fractures: An Opportunity to Improve the Undertreatment of Osteoporosis","volume":"103","author":"Smith","year":"2021","journal-title":"J Bone Joint Surg Am."},{"issue":"15","key":"bib32-20250430","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2106\/JBJS.18.01229","article-title":"Bone Health Optimization: Beyond Own the Bone: AOA Critical Issues","volume":"101","author":"Anderson","year":"2019","journal-title":"J Bone Joint Surg Am."}],"container-title":["Journal of Bone and Joint Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.22.00469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:34:35Z","timestamp":1787751275000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.22.00469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,12]]},"references-count":32,"journal-issue":{"issue":"24","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.22.00469","relation":{},"ISSN":["0021-9355","1535-1386"],"issn-type":[{"value":"0021-9355","type":"print"},{"value":"1535-1386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,12]]}}}